A Prospective Observational Study on Discontinuation of Medication of Shinbaro Capsule
NCT ID: NCT02064634
Last Updated: 2016-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
6700 participants
OBSERVATIONAL
2014-05-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate the Safety of 'Shinbaro Capsule'in Patients With Osteoarthritis
NCT01604239
Efficacy of Shinabro in Hand Osteoarthritis
NCT01910116
Efficacy and Safety of Shinbaro Capsule
NCT01535417
Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury
NCT00597818
Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis
NCT00486434
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Shinbaro (only)
No interventions assigned to this group
Celecoxib (only)
No interventions assigned to this group
Shinbaro + NSAIDs
No interventions assigned to this group
Shinbaro + Celecoxib
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Within 2 weeks prior to participation, not taken anti-inflammatory analgesic drug such as the Shinbaro Capsule, Celecoxib Capsule and NSAIDs(non-steroidal anti-inflammatory drugs)
* Written consent form voluntarity
Exclusion Criteria
* Diagnosed with clinically significant phycological disorder, and taking medication
* Participated in a clinical trial within 4 weeks
* Pregnant or lactating woman
* History of malignant disease within the previous 5 years
* Patients who seem not to participate in the study at investigator's discretion
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Green Cross Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center
Seoul, Sonpa-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GCSB_OS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.